3692 — Hansoh Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$192.43bn
- HK$153.55bn
- CNY15.03bn
Factbox: The race to launch first weight-loss pill
Hansoh Pharma hits 4-1/2-year peak on higher profit, dividend
Factbox: Drugmakers racing to launch the first weight-loss pill
Live Markets: Chinese biotech licensing deals draw U.S. interest despite modest size, Macquarie says
Focus: US pharma bets big on China to snap up potential blockbuster drugs
Brief: Hansoh Pharmaceutical Says Aumolertinib Mesilate Tablets Approved By MHRA For Marketing
Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval
Brief: Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals
Brief: Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA
Brief: Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10542 Capsules Issued By NMPA
Brief: Hansoh Pharmaceutical Says Clinical Trial Approval For HS-20118 Tablets Issued By NMPA
Brief: Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10510 Tablets Issued By NMPA
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Alphamab Oncology leads slide in HK pharma stocks on Trump's plan to trim medicine prices
Brief: Hansoh Pharmaceutical Says Drug Registration Approval Of Fourth Indication Of Aumolertinib Mesilate Tablets Granted By NMPA
Brief: Hansoh Pharmaceutical Says NMPA Granted Breakthrough-Therapy-Designated Drug For HS-20089
Brief: Hansoh Pharmaceutical Receives Drug Registration Approval Of Hengmeida- (Ibrexafungerp Tablets)
Brief: Hansoh Pharmaceutical's Targeted Antibody Drug Conjugate Gets NMPA Breakthrough-Therapy-Designated-Drug
Brief: Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10529 Tablets Issued By NMPA